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Prior research suggests that a high technology start-up's innovative capability and inter-ﬁrmnetwork
inﬂuence its performance and consequently,ﬁrmvaluation. Fewstudies consider their joint inﬂuence
and even fewer consider the temporal change of those effects on ﬁrm valuation. In this study, we
propose that ﬁrm age, a key organizational variable, represents both the development of
organizational routines from a start-up's perspective and the accumulation of accessible
information from an investor's viewpoint. As such, an investor's evaluation of a high technology
start-up's innovative capability and inter-ﬁrmnetwork evolveswithﬁrmage. Using panel data of 170
biotechnology start-ups, our results suggest that the relative value of network status declines while
the impact of innovative capability increases with ﬁrm age. Interestingly, there is a growing
complementary effect of innovative capability and network heterogeneity on ﬁrm valuation. The
implications of these ﬁndings for entrepreneurial practice and theories of ﬁrm capabilities and inter-
ﬁrm network are discussed.
© 2009 Elsevier Inc. All rights reserved.
Keywords:
Capabilities
Absorptive capacity
Alliances
R&D
Valuation
1. Executive summary
Technology start-ups with high growth potential tend to be resource-constrained and often require infusion of ﬁnancial capital. To
do so, investors and entrepreneurs will arrive at an estimate of themarket value or “valuation”. The valuations that investors place on
start-ups will inﬂuence the proportion of equity shares disbursed to raise adequate funds to ensure ﬁrm growth and survival.
Consequently, both entrepreneurs and investors consider valuation to be an importantmetric that determines their equity proportion
and theirﬁnancial returns from investing into the venture. Therefore, understanding the factors affectingnewventures' valuation is an
issue of substantial importance.
Wemaintain that investors will examine information on a start-up's innovative capability and inter-ﬁrm network to arrive at an
estimate of its ﬁnancial value. Information suggesting superior innovative capability and external connections increases the
conﬁdence of investors placed on the start-ups. Prior studies have provided some evidence that innovative capability and inter-
ﬁrm network attributes are positively correlatedwith higher ﬁrmvaluation for new ventures.Whereas studies conﬁrm the positive
linkage between both kinds of information and ﬁrm valuation in start-up context, there are gaps in our understanding of the
combined effect between innovative capability and inter-ﬁrm network andmore importantly, the temporal change of those effects.
Do investors value the potential complementary effect between innovative capability and inter-ﬁrm network? Does one kind of
information becomemore important, or stated differently, does its value impact increase with ﬁrm age? In this study, we posit that
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ﬁrm age represents two processes critical to investors' evaluation—routine development and information accumulation. Hence the
inﬂuences of innovative capability, inter-ﬁrm network and their interaction on ﬁrm valuation vary when start-ups grow older.
Using panel data of 170 biotechnology start-ups over 15 years, our study indicates that the value impact of network status
declines while the value impact of innovative capability increases with ﬁrm age. In addition, there is a strong and growing
complementary effect of innovative capability and network heterogeneity on ﬁrm valuation. Our results suggest that different
kinds of information and their interaction present themselves differently in investors' eyes as start-ups grow older.
Technology start-ups facing complex environments have to make critical decision in terms of allocating their scarce resources
and invest to build either internal capabilities or external partnerships. Our study suggests that the timing of these resource
decisions is a signiﬁcant factor that both entrepreneurs and investors need to consider. We ﬁnd that whereas innovative capability
and external connections are valuable to new ventures, inter-ﬁrm network tends to be more important for valuation purpose at
earlier phases of their life. In later years, investments in building technological capabilities have stronger value enhancing impact.
The study's ﬁndings provide entrepreneurs, investors and managers in technology companies a more precise understanding of
how both types of resources change dynamically to impact ﬁrm valuation.
2. Introduction
Technology-basednewventures oftenneed to secure signiﬁcant amountofﬁnancial resources from investors to furtherdevelop their
technologies intomarketableproducts. Investors assign amarket valueorvaluation to theventure and thenproportionally take anequity
position based on the size of their investment and the agreed valuation. A key problem in assigning a valuation to the high technology
start-up is the tremendous uncertainty associated with its quality. Consequently, investors rely on information that may reveal the
quality of the venture including technological capabilities, corporate governance setup, private placements, and partnershipswith other
ﬁrms among others (Chang, 2004; Deeds and Decarolis, 1997; Janney and Folta, 2003; Sanders and Boivie, 2004; Stuart et al., 1999).
In this study, we focus on two types of information: internally-generated information on the start-up's innovative capability and
externally-veriﬁable informationon the start-ups inter-ﬁrmnetwork attributes. Both these sources of information are likely to inﬂuence an
investor's perceptionofﬁrmvalue. There is an emerging and richdiscussionofﬁrmcapabilities, their origin, evolution and consequences in
the strategy literature. This stream of research suggests that heterogeneous capabilities lead to systematic performance difference among
ﬁrmsbecause capabilities arevaluable, hard to imitate andobtainon resourcemarket (Cockburnet al., 2000; Teeceet al.,1997).Hence, high
technology start-ups with superb innovative capability are valued positively by investors because they are perceived to have higher
prospects for generating commercially successful products and sustaining their competitive advantage (DeCarolis and Deeds, 1999).
Similarly, organizational scholars have extensively documented the positive impact of inter-ﬁrm network (or alliances) on ﬁrm
performance. This literatureposits that since informationandother strategic resourcesareunevenlydistributed in themarket,ﬁrmsneed to
reachbeyond their organizational boundaries to secure the resources critical to developing andmaintaining competitive position (Baumet
al., 2000; Burt,1992; Powell et al.,1996). In absence of accurate information on start-ups, investors even rely onprestige of partners to infer
the quality of start-ups (Stuart et al., 1999). As a result, investors often respond to alliances with other ﬁrms who possess complementary
resources such as ﬁnancial, research and marketing capabilities positively (Chang, 2004; Lavie, 2007). Together, the extant literature
suggests that investors interpret both kinds of information positively when evaluating the ﬁrm valuation of high technology start-ups.
Theoretically, there are gaps in our knowledge of the effects of innovative capability and inter-ﬁrm network on ﬁrm valuation of
start-ups. Prior studies tend to focus on either kind of information but rarely examine their combined inﬂuence. Of particular
interest to strategy scholars is the complementary effect between innovative capability and inter-ﬁrm network (Lavie, 2006;
Zaheer and Bell, 2005). Whether investors appreciate such synergistic effects to estimate ﬁrm value remains an unresolved issue.
An even more pressing question arises with regard to the age-related effects of innovative capability and inter-ﬁrm networks on
ﬁrm valuation, which leads us to the research question: how do the effects of innovative capability and inter-ﬁrm network attributes
on valuation vary with ﬁrm age? It is likely that there may be shifts in the relevance and the emphasis placed by investors on
information as the ﬁrm grows older. This study addresses these gaps by offering a theoretical account of the combined effect of
innovative capability and inter-ﬁrm network and more importantly, their age-related effects on ﬁrm valuation.
3. Theory and hypotheses
3.1. Dynamic impact of innovative capability
There is some collective evidence to show that innovative capability is highly correlated with growth potential and long term
performance of high technology start-ups.We deﬁne innovative capability as the ability to generate novel and useful knowledge or
products (Hagedoorn and Cloodt, 2003; Lee et al., 2001). Innovative capability is crucial for technology start-upswho often achieve
competitive advantage by delivering new products to the market. Lee et al. (2001) found a positive relationship between
innovative capability and sales growth using data on 137 Korean technology start-ups. Other studies reach a similar conclusion that
start-ups' innovative capability positively inﬂuences the likelihood of developing new products and improving ﬁnancial
performance (e.g. Deeds and Decarolis, 1997; George et al., 2002; Shan et al., 1994). In practice, equity analysts and investors often
place great emphasis on innovative capability to make valuation decisions (Bogdan and Villiger, 2008). Below, we develop
arguments to suggest that the inﬂuence of innovative capability on ﬁrm valuation increases with ﬁrm age.
First, ﬁrm age represents development of organizational routines, procedures and policies that have profound consequences on
organizational behaviors. Organizational scholars have attributed lack of reliable and semi-automatic routines as one key reason
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why young ﬁrms are more likely to fail, often called the “liability of newness” (Freeman et al., 1983; Stinchcombe, 1965). When
high technology start-ups grow older, they develop rules, routines and policies that enable them to cope with the uncertainty
embedded in new ventures. It is often considered as the result of organizational learning from either own experience or others'
experience (Klepper, 2001; Levitt and March, 1988). The existence of such organizational routines, procedures, and policies are, in
general, beneﬁcial for technology start-ups. For example, organizations may develop procedures for maintaining, organizing and
reporting research records either form their own operations or by imitating others (Mowery et al., 2002). Those procedures
provide for improved protection of their intellectual property and facilitate research and communication. Consequently, for two
start-ups with comparable levels of innovative capability, the older ﬁrm with more robust routines is likely to extract greater
economic value from its innovations than the younger ﬁrm with fewer routines in place.
Second, from an investor perspective, ﬁrm age also captures information accumulation by providing an accessible and veriﬁable
track record for investors. It is widely accepted that new venture valuation is rife with uncertainty primarily due to lack of historic
records or veriﬁable claimsmade by new ventures (Sanders and Boivie, 2004; Stuart et al., 1999). When technology start-ups grow
older, though, they generate more information either intentionally or involuntarily. For instance, they may present their scientiﬁc
discoveries at academic conferences or demonstrate new products at industry exhibitions. Information about start-ups, their
activities, and successes also circulate in investor communities that tend to be tight, close knit groupswhich operate predominantly
through investment syndicate networks or personal ties (Sorensen and Stuart, 2000). Therefore, the older a technology start-up, it
becomesmore likely that potential investors can access relevant information. Such information accumulationwill help alleviate the
information asymmetry problem surrounding a start-up's valuation, especially when assessing novel technologies.
Therefore, for two start-upswith comparable level of innovative capability, investors will tend to value the older start-up higher
by reducing the valuation discount associated with uncertainty. For example, Vertex Pharmaceuticals ﬁled its ﬁrst patent only one
year after its incorporation. Due to the lack of understanding of its novel “rational drug design” technology and uncertainty
surrounding its internal operations, investors placed a conservative valuation on Vertex. Aastrom Bioscience, founded around the
same time as Vertex, also ﬁled one patent when it was four years old. With comparable novel stem cell technology, Aastrom
Bioscience, however, was able to get a favorable valuation from its investors, due to its relative maturity and because better
information is accessible by the investors on the ﬁrm and its innovative capability. In sum, investors are willing to place higher
valuation on an older start-up than a younger one with equal level of innovative capability because they perceive that the older
ﬁrm is more likely to leverage its innovative capability to achieve commercial success. Therefore, we posit that:
Hypothesis 1. Thepositive effect of innovative capability onﬁrmvaluationwill increasewithﬁrmage for high technology start-ups.
3.2. Dynamic impact of inter-ﬁrm network
The inter-ﬁrm network literature offers an alternative perspective that highlights the external network's impact on ﬁrm
performance (Gulati, 1998; Powell et al., 1996). Inter-ﬁrm networks or strategic alliances are deﬁned as voluntary arrangements
between ﬁrms involving exchange, sharing or co-development of products, technologies, or services (Gulati, 1998). Whereas
multiple beneﬁts have been associated with a ﬁrm's external connections, there are two fundamental beneﬁts that accrue to the
focal ﬁrm: the “transferred” beneﬁt and the “perceived” beneﬁt, corresponding to the “pipes” and “prisms”metaphor proposed by
Podolny (2001). On the one hand, a tie between two ﬁrms can be considered as a pipe transferring information and other resources
between the two. On the other hand, the presence of the tie is also an informational cue on which other players rely to make
inferences about the underlying quality of one ﬁrm (Podolny, 2001:34). Building on this insight, we focus on two inter-ﬁrm
network attributes—network heterogeneity and network status to capture the two beneﬁts respectively.
First, considering the inter-ﬁrm network as an important channel through which technology start-ups exchange information and
other resources with their environment, the more heterogeneous their networks, the more diverse information and other resources
they could receive from other participants in the industry. For technology startups operating in rapidly changing environments, to be
competitive requires not only developing effective in-house innovative capabilities but also access to a diverse information and
resource pool to keep abreast of technological and institutional changes. Prior studies have demonstrated that network heterogeneity
helps high technology start-ups grow and prosper (Baum et al., 2000; Powell et al., 1996). With such understanding, investors often
value start-ups with heterogeneous connections or portfolios of partners positively (Chang, 2004; Lavie, 2007).
Our main focus, though, is to investigate how investors value network heterogeneity of startups as a function of their age. We
maintain that holding other things equal, investors will value an older start-up higher than a younger one with the same level of
network heterogeneity. Following from our discussion in the previous section, ﬁrm age captures the relative robustness of routines
developed by the start-up that enables it to cope with uncertainty more effectively, be it routines for internal innovation (Zahra
and George, 2002) or external collaboration (Kale et al., 2002). Start-ups can also learn how to develop effective partnerships with
other informational sources such as functional experts or industry-speciﬁc consulting ﬁrms. Amgen, a leading biotechnology ﬁrm,
gradually developed procedures to conduct due diligence on selecting and handling partners based on its early years of experience
with alliances (Binder and Bashe, 2008). Firms are likely to differ in how much value they extract from these collaborations. The
strategic alliance literature has provided systematic evidence that alliances do not beneﬁt participant ﬁrms automatically and they
need to learn how to deal with inter-ﬁrm differences such as conﬂict of interest, culture and even differences in infrastructure
(Anand and Khanna, 2000). Older start-ups, assisted with tacit or explicit rules, procedures and policies, are likely to extract higher
value than younger ones with similar collaborations. Stock markets also respond to experienced ﬁrms more positively than
inexperienced ones when they make similar collaboration announcements (Anand and Khanna, 2000; Kale et al., 2002). From an
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investor's perspective, they also have more opportunities to collect information about how start-ups deal with their partnerships
when they grow older, where the internal routinization and learning outcomes are more visible to outside investors. On average,
investors are willing to believe those older start-ups are able to handle partnerships better than their younger counterparts
because the investors collect more information in this regard. In sum, we propose that:
Hypothesis 2a. The positive effect of network heterogeneity on ﬁrm valuation will increase with ﬁrm age for high technology
start-ups.
When faced with uncertainty and incomplete information about technology start-ups, investors may rely on prestige of their
partners to infer their quality. Such endorsement or signaling effect is well documented in ﬁrm valuation literature (Carter and
Manaster, 1990; Stuart et al., 1999). This body of research suggests that start-ups having afﬁliations with prominent endorsers tend
to outperform those without such relationships in terms of time to initial public offering (IPO) and raising more capital at IPO. We
argue that the magnitude of this positive impact of network status on ﬁrm valuation will decrease with ﬁrm age.
First, network status, if understood as a social cue or secondary information used to infer the quality of start-ups, beneﬁts little,
if at all, from internal routine development. In fact, partnering with prestigious partners could be detrimental to older start-ups
with established routines and strategies because their powerful partners may demand changes disruptive to operations of start-
ups (Alvarez, 2001). Rond (2003) documented a partnership between Rummidgen, a new founded biotech ﬁrm and Plethora, an
established pharmaceutical company (real story with pseudo names). Though Rummidgen beneﬁted initially from the
endorsement from an established organization, it became increasingly frustrated with its established partner because its partner
changed the focus of the partnership unexpectedly twice and interfered with its internal research.
Further, the value of endorsement or the associated signaling effect is likely to taper off. As start-ups release more relevant
information to investors by making progress with product development or in attaining investor-set milestones or through other
channels such as academic conferences or presentations to potential investors, network status becomes less critical than it was in the
early stages of the start-up's life. As such, investors may eventually embrace primary information related to ﬁrm quality instead of
secondary information such as prestige of partners tomake valuation decisions (Sanders and Boivie, 2004; Stuart et al., 1999). Shaman
Pharmaceuticals, for example, enjoyed an initially hefty valuation from its partnerships with large pharmaceutical companies and
prominent investors such as Microsoft cofounder Paul Allen. However, as the ﬁrm progressed, its technological limitations were
revealed and investors reduced their expectation. The ﬁrm's valuation sank even with prestigious collaborations after years of
development.Here,weposit that the status signal or “prism” effect of inter-ﬁrmnetworkdecreaseswithﬁrmagebecause investors gain
a better understandingof the focal start-up and rely less on theendorsementeffects of prestigious partners. Therefore,wepropose that:
Hypothesis 2b. The positive effect of network status on ﬁrm valuation will decrease with ﬁrm age for high technology start-ups.
3.3. The complementarity of innovative capability and inter-ﬁrm network
The value of a ﬁrm's internal resources may be ampliﬁed with the presence of connections with external organizations (Lavie,
2006). Firms with superb innovative capability are better prepared to assimilate external information and allocate resources
correspondingly (Cohen and Levinthal, 1990). A heterogeneous network provides access to diverse and effective information ﬂows
and, consequently, provides the opportunity to absorb external information. Zaheer and Bell (2005) found that ﬁrms with
desirable network positions alone are unable to exploit structural beneﬁts. However, those innovative ﬁrms combined with
desirable network positions are most likely to develop new products, a notion consistent with the complementarity of innovative
capability and inter-ﬁrm network. Thus, the extant literature makes a case that ﬁrms with higher internal innovative capability are
more likely to utilize their diverse network access and transform it into higher ﬁrm value by pursuing technological opportunities
and responding to market and competitive shifts.
Questions remain on how this complementary effect between innovative capability and network heterogeneity changes with
ﬁrm age. The organizational learning literature suggests that ﬁrms develop organizational routines to cope with their internal and
external environments (Levitt and March, 1988). Firm age can be viewed a proxy for the development of organizational structures
and routines to support behaviors such as collaborative partnerships or innovation. At a younger age, technology start-ups with
both innovative capability and favorable network positions are less likely to fully realize the combined potential because of
resource constraints or lack of corresponding organizational structures or support. Consequently, the complementary effect is
likely to increase with the presence of organizational routines, infrastructure or even awareness to assimilate external resources
(Sorensen and Stuart, 2000). The alliances formed by start-ups may also stem from expedient needs such as access to ﬁnancial
resources or speciﬁc technological knowledge. With experience, the ﬁrm also develops a capability to strike a balance between
their external collaborations and in-house research (Kale et al., 2002; Rothaermel and Deeds, 2006). Additionally, investors are
likely to perceive the innate synergistic effect with a track record of success and, consequently, place higher value for an older start-
up than a younger onewith a similar opportunity. From a value creation perspective, the complementary effect between innovative
capability and network heterogeneity will likely be stronger when a high-technology start-up becomes more mature and mindful
regarding the alignment between internal capability and its network position. Therefore we postulate:
Hypothesis 3. The positive complementary effect of innovative capability and network heterogeneity on ﬁrm valuation will
increase with ﬁrm age for high technology start-ups.
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4. Method
4.1. Sample
Biotechnology refers to themanipulation of genetic material through recombinant DNA technology, cell fusion andmonoclonal
antibodies. Under this deﬁnition, the biotech industry covers ﬁrms specializing in the human diagnostics and therapeutics (Stuart
et al., 1999). The biotechnology industry represents an ideal research setting to test our hypotheses for several reasons. First,
forming strategic alliances has become a common practice in the biotechnology industry (Powell et al., 1999). Virtually every
biotech ﬁrm is involved in several partnerships with other biotech ﬁrms, pharmaceutical companies, or research institutes. Also,
the capability to produce new knowledge is a critical factor for survival and success of biotech start-ups. The co-existence and
importance of innovative capability and inter-ﬁrm network for biotech start-ups make it an ideal research context for our study.
Additionally, the past two decades have witnessed a phenomenal increase in interest in the biotechnology industry among
researchers, practitioners and policy makers. Consequently, data on biotech ﬁrms such as performance and partnering behavior
have become readily available.
In this study, we took multiple steps to identify sample ﬁrms. First, we checked Bioscan, a comprehensive biotechnology
industry directory, to identify ﬁrms that were active in human diagnostics and therapeutics and founded between 1983 and 1994.
We chose ﬁrms founded in this period of time because we were unable to validate information for older ﬁrms and obtain
information on new ﬁrms due to our panel data design. We also collected ﬁrm level data such as geographic location and ﬁrm size
from Bioscan. This procedure generated over 500 U.S. based dedicated biotechnology ﬁrms. Patenting information was collected
from the NBER patent database, which provides comprehensive coverage on three million US patents issued from 1969 to 1999
(Hall and Ziedonis, 2001). For alliance and valuation data, our primary data source was rDNA.com (formerly Recombinant Capital),
a fee-based data access service and a leading biotechnology data provider. We complemented our data with other sources
including The GEN Guides to Biotechnology Companies, LEXIS-NEXIS, SEC ﬁlings and company websites. After matching data with
each source, the ﬁnal sample size reduced to 170 dedicated biotechnology ﬁrms (DBFs). We tracked these ﬁrms from their
founding years to 1999. In total, we created a panel with 1725 observations for model estimation.
4.2. Dependent variable
Firm valuation is the total market value of the company's equity. It was operationalized as the product of its shares outstanding
and the price per share at the conclusion of a ﬁnancing round. When a start-up experiences a ﬁnancing event (e.g. venture capital
investment or private placement) it will negotiatewith investors on themarket value of the ﬁrm. Our data contains 2524 ﬁnancing
rounds for 170 ﬁrms. On average, there are 1.3 ﬁnancial rounds for each ﬁrm-year observation. To create a panel data on annual
basis, we took following steps: 1) if a start-up had only one ﬁnancial event at year t, we used its valuation for that year; 2) if a start-
up had more than one ﬁnancial event, we used the average valuation for that year; and 3) if a start-up had no ﬁnancing event in
year t, we used linear extrapolation to obtain the valuation data for year t. We used post-money valuation or post investment
valuation because it is comparable to public market value for traded ﬁrms (Nicholson et al., 2005).
For start-ups, valuation is a more accurate ﬁrm performance measure than other ﬁnancial measures because biotech start-ups
typically do not generate stable revenues such that common ﬁnancial measures (e.g. P/E ratio) are inaccurate indicators of
performance or value. In practice, it is of great interest for the shareholders and investors to evaluate the true value of the focal
start-up. For entrepreneurs, their economic returns hinge on howmarkets value their ﬁrm. For investors, ﬁrmvaluation has a direct
effect on their equity stakes and consequently their investment risk and returns. From a theoretical viewpoint, entrepreneurship
scholars emphasize wealth creationwhere ﬁrm valuation can serve as a close proxy tomeasure howmuch wealth is being created.
Our primary source of valuation data was rDNA.com (formerly known as Recombinant Capital or ReCap). rDNA.com collects
valuation records based on each biotech start-up's ﬁnancing history and its valuation data are argued to be more accurate and
comprehensive than other sources (Hand, 2007). Nevertheless, to ensure validity of the valuation data, we cross-checked a sub-
sample of the ﬁrms with other sources: Compustat for publicly traded ﬁrms and Venture Economics for privately held ﬁrms. Both
sources conﬁrmed the reliability of the rDNA data. We used a logarithmic transformation to control for the skewness of the
distribution (Lavie, 2007).
We treated valuation of a ﬁnancing event as the proxy of the valuation for an entire year. We opted for this treatment because
valuations are discrete events for privately held ﬁrms; i.e. valuation is assigned only when there is an investment occurring or other
signiﬁcant ﬁnancial events. Hence, it might be that our treatment is crude to capture the nuances in the change in ﬁrmvaluewithin
a year. To test the robustness of this treatment, we replaced valuation records with public market values whenever they are
available (e.g. if a start-up became publicly traded). The public market valuations are the average of 12 end-of-month daily values
of corresponding years and ought to be a more accurate measure of ﬁrm valuation for the whole year (Lavie, 2007). Our results are
robust to the replacement of valuation data with public market values. We report the results based on discrete data.
4.3. Independent variables
Innovative capability can be gauged from various angles. Due to its complexity, comprehensive survey data are preferred to
capture the multiple facets of the construct. Nevertheless, in our research context, it is infeasible to conduct a survey over time.
Indeed, previous studies using archival data derived a capability measure from observable data (Helfat and Lieberman, 2002).
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Patents are often treated as the proxy of underlying ﬁrm ability to generate new knowledge. Given that our context is the
biotechnology industry, a knowledge intensive and competitive ﬁeld, using patents as proxy of innovative capability is appropriate
(Ahuja and Katila, 2001; Stuart et al., 1999).
Innovative capabilitywas measured by the number of patents granted to the start-up between year t and t−3 and weighted by
its forward citations to account for impact of patents. We determined the date of each patent by its ﬁling rather than granted date
since ﬁling dates reﬂect the timing of inventions more accurately. To ensure that our analysis is not sensitive to the single measure,
we also created an alternative patent-based measure which counts the number of patents with above average level forward
citations, where the average is computed for the entire patent population in speciﬁc technical classes. Our empirical results do not
change materially with respect to the two different measures. We report results associated with citationweighted patent measure.
We constructed two variables to capture the corresponding inter-ﬁrm network attributes. First, we measured Network
Heterogeneity with a Herﬁndahl index of heterogeneity in types of partners such as biotech ﬁrms, pharmaceutical companies,
universities, research institutes, and hospitals (Baum et al., 2000).
Network Heterogeneityit = 1−
X
ij
PAijt
 2 
=NAit
where PAitj is the proportion of all start-up i's alliances that are with partner type j at time t, and NAit is start-up i's total number of
alliances at time t. A start-up with ﬁve alliances, two with pharmaceutical companies, two with biotech ﬁrms, and one with
university would score [1−(2/5)2+(2/5)2+(1/5)2]/5=.124. In fact, this measure is a simpliﬁed ego network measure. To access
the robustness of this measure, we also created an alternativemeasure of network heterogeneity based on structural hole rationale
(Burt, 1992). Speciﬁcally, we obtained the ﬁrm's ego network constraint values by using UCINET 6 (Borgatti et al., 2002) and timed
the constraint value with −1 to simplify interpretation (Zaheer and Bell, 2005). Though the two measures differ in values, they
produce qualitatively similar results. We report the results of Herﬁndahl index measure.
Network Statuswasmeasured as the number of agreements with prestigious partners that are top pharmaceutical companies or
medical schools.We collected the rankings of pharmaceutical andmedical schools fromonemajor industry journal—Pharmaceutical
Executive and U.S. News and World Report respectively (refer to Appendix A). We constructed a group of top pharmaceutical
companies or medical schools based on their average ranking records.
Following common practice in alliance research (Podolny et al., 1996), both network-based variables were computed on a 3-year
backward moving window rather than an annual basis to account for the duration of each alliance. We also conducted sensitivity
analyses to ensure our results were robust to other speciﬁcations such as two or four year window.
4.4. Controls
4.4.1. Market condition
The biotechnology industry is sensitive to stock market conditions. Optimal stock market conditions suggest that the industry
as a whole looks attractive to public investors and may inﬂate ﬁrm valuations. Conversely, an adverse market may force
technologically competent ﬁrms to have deﬂated values. We used the biotechnology stock market index developed by Lerner
(1994a) to account for the impact of market conditions on valuation.
4.4.2. Biotech ﬁrm density
Population density could be viewed as a proxy of industry competition, whichmay potentially reduce performance due to ﬁerce
competition on limited ﬁnancial resources and research opportunities (Hannan and Freeman, 1977). From investors' perspective,
the existence of a large number of competing ﬁrms gives them the option to leverage across ﬁrms innovating on similar products.
To allow for this impact, we counted the number of biotech ﬁrms each year fromBioscan including not only dedicated biotech ﬁrms
but also subsidiaries, foreign ﬁrms and spin-offs to precisely capture the population density effect.
4.4.3. Geographic area
Researchers argue that agglomeration economies and knowledge spill-over effects may be important in developing capabilities
and, possibly ﬁrm valuation (DeCarolis and Deeds, 1999). California and Massachusetts account for almost 40% of US-based
biotechnology ﬁrms (Burrill, 1992). Not surprisingly, geographic access may have a substantial impact on ﬁrm performance. Firms
located in biotech populated areas aremore likely to access leading edge knowledge, meet potential exchange partners and recruit
talented scientists. To control for this geographic effect, we created two categorical variables to indicate whether a start-up is
located in CA or MA areas (1=yes; 0 otherwise).
4.4.4. Technological ﬁeld
Though ﬁrms in our sample are all biotechnology ﬁrms, they compete in different niches within this industry. To account for
sectoral differences, we included indicator variables representing participation in various segments of biotechnology. Following
Stuart et al. (1999), we included four categorical variables to indicate whether the start-up ﬁrm operated in any of the four
segments: Genetic Engineering, Protein Engineering, Immunology and Diagnostics.
Firm Age is the number of years from the date of incorporation. It is both a control variable and also an important moderator in
this study.
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4.4.5. Public company
A signiﬁcant number of ﬁrms in our sample experienced an IPO during the observation period. Since a ﬁrm's valuation may be
substantially different between public and private stages, we introduced a dynamic categorical variable indicating whether a start-
up was public in a speciﬁc year (1=public; 0 otherwise) to control for the effect of capital market access on ﬁrm valuation.
4.4.6. Total alliances
Firms differ in their propensity to partner with external organizations. We used the total number of alliances prior to year t as a
proxy for this underlying propensity. Moreover, this variable controls for the effect of overall network size on ﬁrm valuation.
4.4.7. Equity alliances
Equity alliance is a special case of strategic alliance in that it indicates ﬁnancial resources ﬂowing between the participative
organizations. As discussed earlier, inter-ﬁrm partnerships can be viewed as channels of information and ﬁnancial resource ﬂows.
Since our network heterogeneity primarily focuses on optimizing information ﬂow, it is necessary to parse out the potential effect
of ﬁnancial ﬂows on valuation. We used the total number of equity alliances prior to year t as a proxy.
4.4.8. Valuation t−1
Firms are heterogeneous in terms of the numerous unobservable factors such as organizational culture, managerial skills or
leadership. Exclusion of these important unobserved explanatory variables may substantially bias estimation (Greene, 2000). To
control for these unobserved factors, in particular the serial correlation across years, entering the lagged dependent variable proves
to be an acceptable solution (Jacobson, 1990).
4.5. Analysis
Our ﬁrst analytic approach is to conduct panel regression on explanatory variables. Either ﬁxed effects model or random effects
model is appropriate depending the match between their strength and situational factors. We opted to use random effects model
because: (a) the Hausman test revealed a non-signiﬁcant difference between ﬁxed effects and randomeffects model. In this situation,
random effects model produces unbiased estimates that more efﬁcient than ﬁxed effect model does (Hausman, 1978); (b) to be
consistent with previous studies, we included some time invariant variables such as geographic and segment dummies, which is only
feasible in randomeffectsmodel (Wooldridge, 2001).We created interaction termsbetweenour theoretical variables andﬁrmage. The
sign and signiﬁcance of those interaction terms will suggest the changes in impact of those variables on valuation.
The interaction approach, though straightforward, restricts the interaction relationship by either holding the slope constant or
imposing a parametric functional form. To allow for more ﬂexible interaction detection, we complement the results from the
random effects model with a dynamic panel model, estimated by a regression technique called Minimum Distance Estimation
(MDE). This dynamic panel model is an extension of the conventional ﬁxed effects models with the beneﬁts of controlling for
heterogeneity and making unbiased and efﬁcient estimates (Greene, 2000; Wooldridge, 2001). This dynamic panel model with
MDE has a more ﬂexible assumption on the relationship between error terms and explanatory variables. It allows us to have time-
varying estimates of the parameters (βt) instead of the time-invariant estimates of β and a parametric estimate of interaction term
β⁎ t. Therefore, we are able to capture the relative change of effects without restricting them to be linear ex-ante. We also want to
formally test whether this ﬂexibility is supported by the data as compared to the conventional panel models. MDE provides a way
Table 1
Descriptive statistics and correlations.
Variable Mean S.D. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
1 Firm valuation 3.47 2.16 1
2 Market condition 3.69 .98 .35 1
3 Biotech ﬁrm density 607.43 160.05 .53 .60 1
4 CA area .36 .48 .06 .02 .04 1
5 MA area .14 .35 .02 .00 .01 − .30 1
6 Genetic engineering .24 .43 .05 .02 .03 .04 − .00 1
7 Protein engineering .09 .29 .06 .02 .03 .05 − .01 − .10 1
8 Immunology .14 .34 − .06 − .01 − .02 − .05 .06 − .17 .04 1
9 Diagnostics .17 .38 − .04 .03 .03 − .10 − .02 − .01 .03 − .08 1
10 Firm age 6.47 3.81 .59 .52 .73 − .05 − .02 − .02 − .03 .02 − .02 1
11 Public dummy .60 .49 .61 .44 .59 .02 − .00 .01 .05 − .01 − .02 .67 1
12 Total alliances 8.42 9.54 .50 .36 .51 − .02 − .01 .07 − .01 − .09 − .01 .55 .48 1
13 Equity alliances .79 1.33 .39 .17 .28 .06 − .04 .03 .03 − .07 − .06 .33 .33 .54 1
14 Valuation t−1 3.37 2.11 .80 .40 .55 .06 .02 .04 .06 − .04 − .04 .62 .63 .50 .39 1
15 Innovative capability 3.67 6.71 .35 .13 .26 .09 − .02 .11 .07 − .09 .00 .24 .28 .36 .33 .32 1
16 Network heterogeneity .07 .07 .13 .03 .01 − .03 − .02 .02 .01 .04 .05 .04 .07 − .16 − .08 .02 − .06 1
17 Network status .99 1.49 .35 .18 .26 − .05 − .02 .08 − .02 − .06 − .03 .26 .31 .60 .43 .33 .32 − .05
Total number of valid observations, N=1725.
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to estimate structural form parameters that are a speciﬁc function of reduced form parameters and test which one is more
adequate and is widely used in panel data analysis (Cameron and Trivedi, 2005; Chamberlain, 1984). The econometrics of the MDE
is described in detail in Appendix B.
One potential methodological issue is sample selection bias. The sample ﬁrms with valuation records might be substantially
different from those being excluded due to lack of valuation data. It is plausible that successful and bigger ﬁrms are more likely to
be selected to our sample. We followed the conventional two stage procedure (Heckman, 1979). At the ﬁrst stage, we used ﬁrm
characteristics to predict the possibility of being selected and generate the inverse Mill's ratio (IMR). Then at the second stage, we
entered IMR into the regression to control the selection bias.
5. Results
Table 1 reports the descriptive statistics and correlationmatrix for the variables included. The panel regression of the innovative
capability and inter-ﬁrm network's impact on valuation is reported in Table 2. We enter the control variables in model 1 (Table 2)
and then the theoretical variables in a stepwise manner to test our hypotheses in subsequent models.
Table 2
Random effects GLS estimation of innovative capability and inter-ﬁrm network impact on valuation.
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Constant Included Included Included Included Included Included Included
Inverse Mill's ratio 3.481** 3.133** 3.300** 3.135** 3.078** 3.101** 3.137**
(.415) (.414) (.419) (.415) (.421) (.414) (.424)
Market condition .124** .123** .126** .123** .122** .128** .125**
(.028) (.028) (.028) (.028) (.028) (.028) (.028)
Biotech ﬁrm density/100 .044+ .025 .030 .025 .024 .032 .032
(.023) (.022) (.023) (.022) (.022) (.023) (.022)
CA area .648** .593** .618** .593** .586** .590** .605**
(.085) (.081) (.082) (.081) (.081) (.081) (.082)
MA area − .037 .004 − .014 .004 .009 − .001 − .004
(.086) (.079) (.079) (.079) (.079) (.079) (.079)
Genetic engineering .132* .097+ .090 .098+ .098+ .093 .091
(.064) (.057) (.058) (.058) (.057) (.058) (.057)
Protein engineering .210* .187* .189* .188* .188* .196* .201*
(.091) (.083) (.083) (.083) (.082) (.083) (.083)
Immunology − .158* − .157* − .147* − .156* − .158* − .155* − .148*
(.080) (.072) (.072) (.072) (.071) (.072) (.072)
Diagnostics − .054 − .069 − .075 − .069 − .069 − .073 − .082
(.071) (.064) (.065) (.065) (.064) (.065) (.064)
Firm age − .056** − .045** − .057** − .044** − .042** − .059** − .049**
(.011) (.011) (.012) (.013) (.012) (.012) (.015)
Public dummy 8.578** 7.687** 8.079** 7.693** 7.557** 7.609** 7.699**
(.966) (.965) (.976) (.967) (.981) (.964) (.987)
Total alliances .040** .044** .044** .044** .044** .044** .043**
(.004) (.004) (.004) (.004) (.004) (.004) (.004)
Equity alliances .140** .137** .130** .137** .138** .136** .129**
(.021) (.020) (.020) (.020) (.020) (.020) (.020)
Valuation t−1 .436** .446** .444** .446** .448** .447** .446**
(.015) (.015) (.015) (.015) (.015) (.015) (.015)
Innovative capability .013* .017** .013* .012* .013** .017**
(.005) (.005) (.005) (.005) (.005) (.005)
Network heterogeneity 1.629** 1.701** 1.626** 1.608** 1.635** 1.657**
(.356) (.357) (.359) (.357) (.356) (.361)
Network status .017 .023 .017 .014 .016 .013
(.018) (.019) (.018) (.019) (.018) (.019)
Innovative capability⁎Heterogeneity .067 .029 .066 .077 .084 .052
(.070) (.071) (.070) (.071) (.070) (.074)
Innovative capability⁎Age .002* .003*
(.001) (.001)
Network heterogeneity⁎Age .014 − .032
(.109) (.118)
Network status⁎Age − .005+ − .011*
(.003) (.004)
Innovative capability⁎Heterogeneity⁎Age .054** .015
(.019) (.027)
Wald Chi-square 3376.661 3633.103 3648.942 3626.050 3646.952 3649.701 3675.342
R square .681 .691 .693 .691 .692 .694 .703
N=1725 observations for 170 ﬁrms, (†pb .1, *pb .05, **pb .01, two tailed test.
Unstandardized coefﬁcients are reported; standard errors in parentheses.
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Overall, the control variables exhibit a fairly strong impact on ﬁrm valuation and explain a signiﬁcant portion of the variance
(R-square=.68). The coefﬁcients of IMRarepositive and statistically signiﬁcant (pb .01), suggesting that sample selectionbias indeed is a
relevant concern and justifying its inclusion (Wooldridge, 2001). TheMarket Condition is positively and signiﬁcantly associatedwith ﬁrm
valuation, indicating that ﬁrm valuation is inﬂuenced by the performance of the entire biotechnology industry.
We enter the theoretical variables in model 2 and their interaction terms with ﬁrm age in subsequent models. For example, we
enter Innovative Capability⁎Firm Age inmodel 3 to test H1. Inmodel 7, we enter all the variables to constitute a full model. Model 7
improves model ﬁt over the baseline model signiﬁcantly. With degree of freedom 4 and 1701, the corresponding F statistic is 17.18,
substantively larger than the threshold 3.32 (pb .01). For models with interaction terms, interpretation of a variable's total effect
will be decomposed into direct effect and interaction effect (Jaccard and Turrisi, 2003). Since the direct effects of our main
theoretical variables remain stable across models, the sign and signiﬁcance of the interaction terms can be used to interpret change
in the total effect.
Our hypotheses address the change in relative impact of network and capability variables on ﬁrm valuation with increases in
ﬁrm age. In models 3 and 7, the interaction term between innovative capability and ﬁrm age is positive and statistically signiﬁcant
(β=.002 and .003; pb .05). This result suggests that as a biotech start-up matures, its innovative capability measured by number
of high-quality patents will have larger impact on ﬁrm valuation. Therefore, H1 is strongly supported.
The non-signiﬁcant coefﬁcients of network heterogeneity and ﬁrm age interaction in both models 4 and 7 indicate that the
effect of network heterogeneity on valuation either does not change or does not show a consistent pattern with regard to aging.
Consequently, hypothesis 2a is not supported.
The effect of network status on ﬁrm valuation declines with ﬁrm age. The coefﬁcients of network status are negative in both
models 5 and 7. In model 5, the effect is marginally signiﬁcant (β=− .005, pb .1) but in model 7 it becomes signiﬁcant (β=− .011,
pb .05). Thus, our hypothesis 2b is supported.
Finally, we enter a three way interaction term to examine whether the complementary effect of innovative capability and
network heterogeneity changes over time in a consistentmanner (H3). Inmodel 6, the coefﬁcient of the threeway interaction term
is positive and signiﬁcant (β=.054, pb .01). It remains positive but loses signiﬁcance in the full model. Hence, hypothesis 3 is not
supported if we choose model 7 as the benchmark. We further explore this result with the more sophisticated dynamic panel
model described below.
The restrictive assumptions underlying the traditional interaction approach (requiring an monotonically increasing or
decreasing functional form) as well as the generic panel models (βt=β) may yield inaccurate estimates (Chamberlain, 1982). We
attempt to remedy these restrictions with the dynamic panel model usingMDE. First, we needed to ascertainwhether partitioning
the overall panel into stages is statistically appropriate. To do so, we conducted an overall test to examine the statistical difference
between the dynamic panel and the generic panel model. The test statistic (similar to likelihood ratio test statistic) revealed
signiﬁcant different between the two speciﬁcations, rejecting the null hypothesis (Chamberlain, 1984).
In Table 3, we report the results of dynamic panel model using MDE. Due to the speciﬁcation of our model and the
computational power required, we can only allow for a balanced panel or equal length observation for each subject. To retain the
maximum number of sample ﬁrms and the longest observation period, we had to truncate our sample to 152 ﬁrms with an
observation period of seven years. We are particularly interested in the change of coefﬁcients of the key variables. Essentially the
results in Table 3 buttressed the results obtained from random effects GLS estimation. For example, the impact of innovative
capability on ﬁrm valuation increases with ﬁrm age. We also found that the effect of network heterogeneity on ﬁrm valuation
ﬂuctuatedwith aging, conﬁrmingwhy the GLS estimation could not detect a signiﬁcant interactionwith conventional approach. To
assist interpretation, we plotted the impact of innovative capability, network heterogeneity and their interaction in Figs. 1 and 2. In
Fig. 1, we plot the relationship between innovative capability and valuation as moderated by ﬁrm age. In Fig. 2, we plot the
standardized estimates from the MDE model (Table 3). We see that there is a positive and increasing coefﬁcient for innovative
capability and the complementary effect between network heterogeneity and innovative capability as a function of ﬁrm age. As
Table 3
Results of minimum distance estimation.
Predicators Dependent variable: ﬁrm valuation
Age=2 Age=3 Age=4 Age=5 Age=6 Age=7 Age=8
Control variables Yes Yes Yes Yes Yes Yes Yes
Innovative capability − .044+ − .005 .004 .003* .011** .023** .057**
(.026) (.010) (.006) (.001) (.003) (.003) (.003)
Network status .035* .021* .001 0.003 − .028** − .051** − .055**
(.016) (.009) (.017) (.015) (.013) (.012) (.012)
Network heterogeneity 2.943** 0.471* 2.701** 4.157** 2.803** 3.728** 3.086**
(.221) (.213) (.196) (.210) (.218) (.276) (.308)
Innovative capability⁎Network heterogeneity .033 .055 .157* .138* .231** .483** .526**
(.164) (.119) (.073) (.060) (.059) (.059) (.037)
N=152 ﬁrms, T=7 years, 1064 valid observations.
+pb .10, *pb .05, **pb .01, two-tailed test.
Balanced panel, starts from age=2 due to lagged valuation.
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predicted, network status has its highest impact on valuation in the early years but steadily decreases over time. Together, these
ﬁndings raise some interesting theoretical and practical implications of a ﬁrm's networks and its capabilities as a function of its age.
5.1. Alternative explanations
Statistical results may be spurious if the hypothesized relationships are confoundedwith alternative explanations. In this study,
besides generating multiple measures on each key variable, we also conducted additional analyses to rule out several major
confounding arguments. First, because we use patents to derive our innovative capability measure, it is likely that we measure the
propensity of the ﬁrm to patent rather than its ability to innovate. After all, unlike academic publications, patents are proprietary
rights conferred to business ﬁrms that can be used as a strategic weapon either to protect their intellectual property or attack
potential competitors (Hall and Ziedonis, 2001). To tease out this possibility, we collected information on patent claimswhich are a
fairly good proxy of the coverage of a ﬁrm's proprietary knowledge and useful for protecting or attacking purposes (Lerner, 1994b).
We found that this patent scope variable is almost orthogonal to patent citations and adding this new variable barely changes the
results.
Though we controlled for valuation at t−1, we did not check if such a round was the ﬁrst or subsequent round of ﬁnancing.
Therefore, we introduced controls for the ﬁnancing round and the results are robust to this change. Further, age was negative and
signiﬁcant in our models (Table 2), which was puzzling becausewe expect that age to have a positive effect on valuation.We found
that the coefﬁcient for age turns negative when the lagged measure for valuation at t−1 is introduced. Our speculation is that the
lag ﬁrm valuation variable may be correlated with ﬁrm age and hence captures the positive effect attributable to ﬁrm age. A
common solution is to remove either variable from analyses. We experimented with removing the lag variable and found that our
Fig. 1. Moderating effect of ﬁrm age on innovative capability and valuation.
Fig. 2. Standardized estimates of factors impacting ﬁrm valuation.
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results are not sensitive to the inclusion/exclusion of such variable. The hypothesized effects became even stronger without the lag
variable. Nonetheless, lag ﬁrm valuation is an important control for autocorrelation and signiﬁcantly improves model ﬁt. So we
decided to keep it as a control. Further, it is possible that the temporal pattern could be attributed to the speciﬁc time frame
selected. To verify, we added calendar year dummies to our analyses. In addition, we conducted analyses with observations after
ﬁrms became public to test whether our theory is sensitive to the transition from private to public status. Neither treatment
materially changes our results.
6. Discussion and implications
In this study, we examine the relative temporal impact of innovative capability and inter-ﬁrm network on valuation of the start-up
ﬁrm. While we ﬁnd that both internally-developed resources (innovative capability) and external resources (network heterogeneity
and network status) have a positive impact on ﬁrmvalue, these variables differ in their relative impactwhen start-ups growolder.We
ﬁnd that the positive effect of network status on valuation decreases with ﬁrm age. Concurrently, capabilities in the form of ability to
generate new knowledge have an increasingly positive effect on valuation as start-ups become older. Our results provide critical
insights into the changing impact of types of resources on value creation in entrepreneurial ﬁrms. The ﬁndings have signiﬁcant
implications for theories on organizational capabilities, networks, and wealth creation and are discussed next.
6.1. How and when do capabilities matter?
The literature on organizational capabilities has tended to focus on the successful deployment of a capability, i.e. executing a
capability increases performance, but rarely considers the temporal consequences of the development of capabilities. In arguing for
dynamic capabilities, Teece et al. (1997)note that theheterogeneity inﬁrms' abilities to continually reconﬁgure routines and resources
to meet evolving competitive conditions is the premise for sustained performance differences across ﬁrms. While there are some
conceptual studies which argue that the timing of capability development has performance implications (e.g. Helfat and Peteraf,
2003), to our knowledge, this is the ﬁrst empirical study to document a truly dynamic scenario of capabilities and its effects.
Our results conﬁrm the positive effect of innovative capability on ﬁrm performance in technology start-ups, consistent with
other studies (e.g., Baum et al., 2000; Rothaermel and Deeds, 2006). However, our interaction terms with age (Table 2) and the
MDE results (Table 3) provide an interesting twist to the interpretation of existing literature. That is, the effect of the internal
capability, innovative capability in this study, may initially detract from value creation but subsequently increases in its relative
positive impact on value creation. This ﬁnding is consistent with theoretical arguments made by Sapienza et al. (2006) who argue
that capability investments during internationalization of new ventures may initially decrease survival rates but subsequently
enhance growth prospects. By allowing the slope to vary in ourMDEmodel, we show that initially there could be a negative impact
but this effect turns positive after a few years. Future studies could follow our approach to unravel the dynamism in value creation
or performance as driven by investments in capabilities.
Results of this study also conﬁrm arguments made by Cockburn et al. (2000). In a study of pharmaceutical ﬁrms, these authors
found that successful ﬁrms were those that invested in building R&D capabilities long before any payoffs could be expected.
Similarly, our study shows that the relative impact of innovative capability on valuation is negligible and then subsequently
increases with ﬁrm age. George (2005) found that when an organization learns from the experience of deploying a core capability,
it can parlay these beneﬁts into the development of complementary capabilities, thereby increasing performance not just through
experiential learning within a core capability but also through a multiplicative effect on complementary capabilities. This study's
results suggest a similar explanation that capabilities gain traction over time and generate value with experience in deploying
these capabilities.
6.2. The timing of inter-ﬁrm network formation
The ﬁndings of this study provide valuable information for the role of networks in high technology start-up ﬁrms. Network or
alliance studies conﬁrm the value of such ties for R&D, product development and ﬁnancial performance amongothers. This study adds
to this literature by suggesting that the value of such ties is greater at early stages of the ﬁrm's life cycle, ﬁndings that havemanagerial
relevance aswell. For example, though alliances provide a strong endorsement effect in the absence of any credible information of the
start-up ﬁrm's capabilities, such endorsement effects prove to be more valuable earlier rather than later (Stuart et al., 1999).
Whereas our study considered the impact of the external network on ﬁrm value, it is possible that these alliances may have a
signiﬁcant payoff in other intermediate outcomes that do not necessarily enhance value directly. For example, alliances as sources
of information and R&D could be positive for ongoing research projects (Hoang and Rothaermel, 2005), but these projects may not
necessarily materialize to create value within the observation period that we consider. Our study provides some evidence for the
declining value of ﬁrm level partnerships over time. We use two measures of network characteristics—heterogeneity and status—
future research could explore the implications of a broader set of network variables. For instance, social capital theory suggests that
network embeddedness, a rather macro level network construct, matters in terms of enhancing performance. Though we
considered only inter-organizational relationships in this study, it would be useful for scholars to understand the temporal impact
of social or personal networks on ﬁrm value or performance of entrepreneurial ﬁrms (Florin et al., 2003). It is possible that the
value of social ties also varies over time or is contingent upon the presence of other internal organizational capabilities. The results
of this study encourage researchers to consider the dynamic effects of other network variables on performance.
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Our study reveals an intriguing pattern regarding the dynamic impact of internal vs. external resources on ﬁrm performance.
Though the direct impact of network variables such as network heterogeneity was unchanged over time, the complementary effect
between network heterogeneity and innovative capability or leveraging the network's impact may increase over time. Therefore, this
result suggests that though we may observe the increasingly important role of organizational networks (Powell et al., 1996), their
relative importance tends to change with ﬁrm age. Our study encourages further studies into the underlying causal mechanisms and
the dynamism in their impact in start-ups.
We do, however, ﬁnd a strong and growing complementary effect between innovative capability and network heterogeneity on
ﬁrm valuation. This result is consistent with our theoretical arguments that ﬁrm age represents routine development and
information accumulation. The development of routines has an enabling effect or boosts the complementary effect. Investors can
collect, analyze, and infer the track record of technology start-ups as they grow older; where the total effect reﬂects an increasing
ﬁrm value. Thus our study contributes to the strategy literature by showing how ﬁrms create value by creating synergies between
their innovative capability and inter-ﬁrm networks.
6.3. Wealth creation and entrepreneurship
A critical part of the theoretical discourse on wealth creation is the impact of resources in entrepreneurial ﬁrms. For example,
entrepreneurship theories discuss the importance of bricolage, or the ability to combine resources, and bootstrapping, or the
stretching of scarce resources, to sustain a start-up ﬁrm (Baker and Nelson, 2005). In motivating organizational scholars to
consider research in this area, Hitt et al. (2001) suggest that entrepreneurship and strategy literatures need to be integrated to
examine entrepreneurial strategies that create wealth. These authors noted that outcomes from creation (i.e. entrepreneurship)
and exploiting current advantages while exploring new ones (i.e. strategic management) can lead to tangible wealth creation.
Whereas accounting measures of performance are indeed important, it is the ultimate outcome of wealth creation for the
entrepreneurial team that may serve to motivate entrepreneurial behavior and spawn other new ventures (Stuart and Sorenson,
2003), enhance investor support and conﬁdence (Nicholson et al., 2005), or increase the likelihood of subsequent partnering
behavior (Anand and Khanna, 2000).
By estimating the time-varying effects of network resources and capabilities on valuation, we add to our understanding of the
dynamismof types of resources and their relative impact onwealth creation.Whilewemeasuredﬁrmvaluation in this study, there is a
direct linkage between ﬁrm valuation and wealth creation. In start-ups, we argue that the ﬁrm-level network serves as both an
information conduit and as informational cue. Our ﬁndings indicate that, from a dynamic perspective, at least the status endorsement
effect declines due to the reduced uncertainty about the entrepreneurial opportunity and the increasedmaturity of start-ups in terms
of developing routines, rules and procedures. For managerial practice, we note that while both innovative capability and external
networks matter in terms of boosting ﬁrm valuation, it is the timing of deploying these resources that is critical. Start-ups seeking to
maximize valuation should be cognizant of the payoffs for attracting partners at different points in ﬁrm age.
7. Limitations and conclusion
Researchers need to exercise some cautionwhen generalizing our results. First, our ﬁrms are drawn from a single industry. This
sampling technique helps rule out certain methodological threats but restricts the ability to generalize the conclusions to a larger
population. Nevertheless, we believe the general social processes underlying our study holds across settings that examine high
technology ﬁrms. It is possible that much of the dynamic effect captured in our study is lost in non technology-intensive
environments. The persistence (or absence) of time-varying effects across industry types would shed more light on the pacing of
capability development or the temporal dynamics within start-up ﬁrms, areas that merit further investigation.
Another limitation is that our measure of innovative capability is crude. Future studies can employ a more ﬁne-grained data
(e.g. survey data, publication citation analysis) to gauge innovative capability. Our modeling technique enables us to measurewith
greater accuracy the dynamic effects of the independent variables. We achieve this goal at the expense of other aspects: the
restrictions of the model exclude ﬁxed variables, including geographic and technical ﬁeld control variables because the dynamic
panel model is fundamentally a ﬁxed effects model. It is also computationally complex and time consuming due to the iterative
computations involved. We encourage researchers to consider variations of this technique and possibly develop a simpliﬁedmodel
that can also address the time-varying effects problem. Finally, our study leaves a few important questions unanswered. For
example, we do not knowwhat happens to the effects on ﬁrm valuation in the long run. Does the capability/network effect reach a
plateau effect after increasing or declining when routine development and information accumulation reach their equilibrium stage
when new routines or information contribute little to ﬁrm value? Or as Helfat and Peteraf (2003) suggested, do ﬁrm capabilities
undergo a life cycle with periods of growth and decline? If this is the case and we extend our observation period long enough, it is
possible that our conclusions on capability or network effects may change.
Limitations aside, our studymakes critical contributions to the literature on the role of dynamic resources in ﬁrms. In this paper,
by drawing from strategic and social frameworks, we offer a more complete response to the question: how do internal capability
and external networks matter? Our study not only replicates the bulk of the literature on the direct effects of internal capabilities
and network characteristics, but also more importantly, extends the literature by exploring the age related contingencies. We
found that in our sample of biotechnology start-ups, the value of internal, innovative capabilities increased while the value of
external network relationships decreased over time. We encourage future research to investigate the dynamism associated with
organizational growth and the time-varying effect of different types of resources.
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Appendix A
Section B.1. Minimum distance estimator of augmented panel data model
The model we consider is the following:
yit = βt;0 + βt;1xit;1 + N + βt;k−1xit;k−1 + γtAit + δtcit + eit ;8i; t ðA:1Þ
Where cit is the unobservable ﬁrm-speciﬁc effect, which is allowed to vary over time in our model:
cit = α1ci;t−1 + α2Ai;t−1 + ηt 8t N 1 ðA:2Þ
From Eqs. (A.1) and (A.2), we have:
yit = βt;0 −
δtα1
δt−1
βt−1;0 +
δtα1
δt−1
yi;t−1 + βt;1xit;1 + N + βt;k−1xit;k−1 + γtAit
− δtα1
δt−1
βt−1;1xit−1;1 + N + βt−1;k−1xit−1;k−1
 
þ δtα2 − γt−1
δtα1
δt−1
 
Ai;t−1þ eit−
δtα1
δt−1
ei;t−1 + δtηt
  ðA:3:1Þ
The unrestricted version of Eqs. (A.3.1) and (A.3.2) takes the form of
yit = ut;1 + ut;2yi;t−1 + ut;3xit;1 + N + ut;k + 1xit;k−1 + ut;k + 2Ait
+ ut;k + 3xit−1;1 + N + ut;2k + 1xit−1;k−1þut;2k + 2Ai;t−1þvit ðA:3:2Þ
Because the lagged dependent variable yi,t−1 in Eqs. (A.3.1) and (A.3.2) is an explanatory variable and correlated with error
term εi,t−1, an ordinary least squares (OLS) regression would be biased. Therefore, we resort to instrumental variable regression.
Let's denote:
Wit = 1 yi;t−1 xit;1 N xit;k−1 Ait xit−1;1 N xit−1;k−1 Ait−1
 
ðA:4Þ
Then we can rewrite Eq. (A.3.2) as
yit = Witut + vit ðA:5Þ
We choose our instrumental variable as
Zit = 1 xit;1 N xit;k−1 Ait xit−1;1 N xit−1;k−1 Ait−1 xit−2;1 N xit−2;k−1 Ait−2
 
ðA:6Þ
Which automatically satisﬁes the criteria of instrumental variable choice:
E Z VitWit
 	
≠ 0 and E Zitvitð Þ = 0:
Ranking of top pharmaceutical companies and medical schools.
Ranking Pharmaceutical companies Medical schools
1 Pﬁzer Harvard
2 Glaxo Wellcome Johns Hopkins
3 Merck Duke
4 AstraZeneca Yale University
5 Bristol–Myers Squibb U of California at San Francisco
6 Aventis Washington U, Mo.
7 Novartis U of Pennsylvania
8 Johnson & Johnson Columbia
9 Eli Lilly Cornell
10 Roche Stanford
To compute the ranking, we ﬁrst gathered each year's ranking from Pharmaceutical Executive (1999–2005) and US news & world report (1990–1998). Then we
average their ranking across years and sort the order again to generate a new ranking.
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Stack up individual Wit' s, Zit' s and yit' s,
Wt = W1t ; N ;WNtð ÞV
Zt = Z1t ; N ; ZNtð ÞV
yt = y1t ; N ;yNtð ÞV
We can get our two stage least squares (2SLS) estimator for φt for all t≥3:
ut;2SLS = W VtZt ZVtZt
 	−1Z VtWt
h i−1
W VtZt ZVtZt
 	−1Z Vtyt ðA:7Þ
Because our theoretical model (A.1)–(A.3.2) concerns about the connections of coefﬁcients over time, the 2SLS estimator could
not capture this dynamic structure. We proceed to derive three stage least squares (3SLS) estimator of all our coefﬁcients.
To do that, ﬁrst we need to obtain the 2SLS residuals for each period:
vˆit = yit − Witut;2SLS ðA:8Þ
Deﬁne
vˆt = vˆ1t ; N ; vˆNt
 	V ðA:9Þ
Sts =
1
N
vˆVt vˆs ðA:10Þ
Then the matrix of mean squares and cross products of 2SLS residuals S would have the t,sth element as Sts.
Now deﬁne
vech xið Þ = 1 xi1;1 N xi1;k−1 Ai1 N xiT ;1 N xiT ;k−1 AiT
 V ðA:11Þ
X = vech x1ð ÞV N vech xNð ÞV
 V ðA:12Þ
M¯ = X XVXð Þ−1XV ðA:13Þ
W =
W3 0 0
0 O 0
0 0 WT
0
@
1
A ðA:14Þ
Y = y3 N yTð ÞV ðA:15Þ
Then
Φ3SLS = W V S
−1  M¯
 
W
h i−1
W V S−1  M¯
 
Y ðA:16Þ
Where Φ3SLS=(ϕ3…ϕT)′ and ϕt is the 3SLS counterpart of φt,2SLS.
So far, the 3SLS estimator takes into consideration the dynamic structure of coefﬁcients, but what we are interested in is not Eq.
(A.3.2). Indeed, our ultimate goal is to recover the parameters in Eq. (A.3.1), or the βs, γs and δs. To do that, we need to conduct the
minimum distance estimation technique because apparently non-linear combinations of βs, γs and δs constitute the counterparts
of our 3SLS estimator in Eq. (A.3.1). The essence of this technique is to create a distance metric between model parameters and
their sample analogs. This technique is similar to the traditional OLS in the sense that the distance measure OLS utilizes is the
distance between true and estimated values and the parameters, which minimize the sum of squared distances.
Formally, denote
θ = β2;1 N βT ;1 N β2;k−1 N βT;k−1 γ2 N γT δ3 N δT α1 α2
 V ðA:17Þ
Parameters start from the second period because the lagged dependent variable is included, so t=1 is treated as the initial
period. δs start from the third period because δ2 is set to 1.
Then f(θ)=[ f(θ)3…f(θ)T]′ is the Eq. (A.3.1) counterpart of Φ3SLS, excluding all intercepts. To be more speciﬁc, f(θ) is the Eq.
(A.3.1) version parameter estimate, andΦ3SLS,no intercept=[(0 I2k+1)⊗IT−2]Φ3SLS is the Eq. (A.3.2) version parameter estimate. The
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reason we use f(θ) is natural, since from Eq. (A.3.1), we can see coefﬁcients for explanatory variables are actually non-linear
functions of fundamental parameters in θ.
Denote
Λˆno intercept = 0 I2k + 1
 	 IT−2
  W V S−1  M¯
 
W
h i−1
0 I2k + 1
 	 IT−2
 V ðA:18Þ
We have our minimum distance estimator of θ:
θˆmin dis = argmin
θ
Φ3SLS;no intercept− f θð Þ
h iV
Λˆno intercept
−1 Φ3SLS;no intercept − f θð Þ
h i
ðA:19Þ
Section B.2. Test of augmented panel data model vs. traditional panel data model
The above model is called augmented panel data model because it differs from traditional panel data model in the essence that
we allow for time-varying coefﬁcients. A natural question could be raised: is it necessary to create time-varying coefﬁcients? Or
maybe time-ﬁxed coefﬁcients could do a decent job? To analyze this, we create two competing hypotheses:
H0. Effects of explanatory variables are time-ﬁxed.
H1. Effects of explanatory variables are time-varying.
If H0 is true, our model becomes
yit = β0 + β1xit;1 + N + βk−1xit;k−1 + γAit + cit + eit ; 8i; t ðA:20Þ
Which leads to:
yit = yi;t−1 + β1 xit;1 − xit−1;1
 
+ N + βk−1 xit;k−1 − xit−1;k−1
 
+ γ Ait − Ai;t−1
 
þ eit − ei;t−1
 
ðA:21Þ
Now
θfixed = β1 N βk−1γð Þ V ðA:22Þ
The minimum distance estimator for θﬁxed solves
min
θ
Φ3SLS;no intercept− f θfixedð Þ
h iV
Λˆno intercept
−1
Φ3SLS;no intercept − f θfixedð Þ
h i
ðA:23Þ
Denote
d1¼ Φ3SLS;no intercept− f θˆmin dis
 h iV
Λˆno intercept
−1 Φ3SLS;no intercept − f θˆmin dis
 h i
ðA:24Þ
d2¼ Φ3SLS;no intercept− f θˆfixed
 h iV
Λˆno intercept
−1 Φ3SLS;no intercept − f θˆfixed
 h i
ðA:25Þ
It has been proved (Chamberlain, 1982, 1984) that, under the null H0,
d2 − d1→
d χ2T−2ð Þk + T ðA:26Þ
So, if the statistic d2−d1 is larger than the critical value χα,(T−2)k+ T2 , H0 is rejected.
Section B.3. Single parameter test
To do this, we need to ﬁnd variance of θ by the usage of δ-method.
If F=∂f(θ)/∂θ′,
then Δ=var(θ ̂min dis)=[F′Λ̂no intercept−1 F]
−1
.
It's been proved (Chamberlain, 1982, 1984) that
θˆmin dis − θ0→
d N 0;Δð Þ ðA:27Þ
Hence, to test whether any parameter is signiﬁcantly different from 0, our test statistic would be θˆjﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
varð θˆjÞ
p , which is
asymptotically normal (0,1) under the null H0: θj=0.
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